Видео ютуба по тегу Nimbus Therapeutics

Biotech Series: Nimbus CEO Abbas Kazimi on Leading the Future of Precision Therapeutics
Biotech Series: Nimbus CEO Abbas Kazimi on Leading the Future of Precision Therapeutics
Nimbus Therapeutics testimonial
Nimbus Therapeutics testimonial
Enabling Secure Collaboration for Biotechs With Egnyte - A Nimbus Therapeutics Story
Enabling Secure Collaboration for Biotechs With Egnyte - A Nimbus Therapeutics Story
Rebecca Carazza (Nimbus Therapeutics): Leveraging ChemAxon tools to automate Nimbus’ SDFile curation
Rebecca Carazza (Nimbus Therapeutics): Leveraging ChemAxon tools to automate Nimbus’ SDFile curation
Jeb Keiper
Jeb Keiper
Base to Base biotech podcast 13: Syngene commits to US market, and Nimbus Therapeutics on...
Base to Base biotech podcast 13: Syngene commits to US market, and Nimbus Therapeutics on...
Ep127: Jeb Keiper on Computational Drug Discovery
Ep127: Jeb Keiper on Computational Drug Discovery
Фармацевтический гигант Takeda объявил о блестящих результатах 3-й фазы испытаний препарата
Фармацевтический гигант Takeda объявил о блестящих результатах 3-й фазы испытаний препарата
Better Living through Computational Chemistry
Better Living through Computational Chemistry
The $4 Billion Deal that changed Bhaskar's Career
The $4 Billion Deal that changed Bhaskar's Career
NEXUS North America 2023: Assessing External Resource KPIs
NEXUS North America 2023: Assessing External Resource KPIs
Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
Nimbus Live Interviews
Nimbus Live Interviews
Japan's Takeda to buy Nimbus' psoriasis drug for up to $6B #shortvideo #takeda #nimbus #psoriasis
Japan's Takeda to buy Nimbus' psoriasis drug for up to $6B #shortvideo #takeda #nimbus #psoriasis
DMPK Insights #4: DMPK Past, Present and Future – A Festive Tale
DMPK Insights #4: DMPK Past, Present and Future – A Festive Tale
The positive results of the phase 2b clinical trial for the #TYK2 inhibitor drug TAK-279 #fda
The positive results of the phase 2b clinical trial for the #TYK2 inhibitor drug TAK-279 #fda
JP Morgan 2024 – Graham Heap
JP Morgan 2024 – Graham Heap